OSE Immunotherapeutics SA
OSE Immunotherapeutics SA (OSE.PA) Stock Overview
Explore OSE Immunotherapeutics SA’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
115.9M
P/E Ratio
2.93
EPS (TTM)
$1.46
ROE
0.52%
OSE.PA Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of OSE Immunotherapeutics SA (OSE.PA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 44.26, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $10.06.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 2.93 and a market capitalization of 115.9M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus; BI 765063, which is in Phase I clinical trial to treat solid tumors; and BiCKI, a novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets to fight primary and secondary resistance mechanisms developed by cancers. The company's products also comprise OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis; and OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA is headquartered in Nantes, France.
Nicolas Poirier
64
22, boulevard Benoni Goullin, Nantes
2015